DUOBRII FDA approval date

The FDA approved DUOBRII on 25 Apr 2019.

FDA approval date
25 Apr 2019

Drug identity has not yet been verified against registry records

Also recorded as HALOBETASOL PROPIONATE; TAZAROTENE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-04-25DayDUOBRIIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209354", "applicant_as_listed_by_fda": "BAUSCH", "brand_names": ["DUOBRII"], "active_ingredients": ["HALOBETASOL PROPIONATE", "TAZAROTENE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190425", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026